Cancer Research Horizons Partnership
Cancer Research Horizons is a wholly owned subsidiary of Cancer Research UK, acting as its translational arm to advance bold research innovations. Cancer Research Horizons operates at the interface between research and industry to accelerate the translation of innovative science into treatments and diagnostics for patients around the world.
Photo: GettyImagesKI and Cancer Research Horizons announce 5-year partnership
Karolinska Institutet and Cancer Research UK’s innovation engine, Cancer Research Horizons, have established a 5-year strategic partnership in November 2022, dedicated to accelerating the translation of academic cancer research into improved treatments for patients.
Cancer Research Horizons Portfolio
Cancer Research Horizons is accelerating ground-breaking discoveries into life-improving treatments through robust and sustainable pipeline. Their therapeutic portfolio spans the entire drug discovery process, from early stage discovery through to first-in-human studies and beyond. Cancer Research Horizons played an instrumental role in bringing 14 new cancer drugs to market. Now, they are continuing to fast-track scientific breakthroughs into patient benefit through pioneering research.
Q&A drop-in session with Cancer Research Horizons, 29 April 2025
The next Q&A drop-in session with Cancer Research Horizons will be held on 29 April 2025, 12:30 - 13:30h, online.
During this session, you will get the chance to ask any questions on the grants or other opportunities to work with Cancer Research Horizons.
No registration is needed, just join the meeting. The link can be found here.
Current calls and events
Photo: Getty ImagesTherapeutic Catalyst Grant
Cancer Research UK Therapeutic Catalyst Awards were launched in late 2021 and have been a great success. The scheme operates as a collaborative venture between research scientists and drug discoverers within Cancer Research Horizons to accelerate the translation of novel ideas for therapeutic discovery. Awards can be up to £250,000 to support a 12–18-month proposal. There are 3 rounds of applications per year held in February, June and October.
Next expression of interest deadline: 6 June 2025.
Photo: Getty ImagesChildhood Cancer Therapeutic Catalyst
Childhood Cancer Therapeutic Catalyst accelerates the translation of discovery research into novel therapeutics. It seeks projects with strong potential to deliver novel therapeutics for children and young people with cancer. This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering.
Successful projects will receive up to £250k for up to 18 months.
Photo: Getty ImagesData Catalyst
The Data Catalyst aims to maximise the impact of cancer datasets that may have commercial value. The scheme does this through providing funding and support to help researchers make these datasets more accessible and usable by third parties.
The end goal is to produce a high-quality cancer dataset that adheres to FAIR principles (findable, accessible, interoperable, and reusable) and can be made available to third parties for further research and product development.
Photo: eko pramono from PixabaySeed Fund
The Seed Fund builds on 25 years of creating and building successful start-ups. Managed by Cancer Research Horizons' dedicated Ventures team, the fund helps bridge one of the most challenging stages of start-up creation: attracting early-stage risk capital.
Set up with a cornerstone investment of £15m from Cancer Research UK, the fund now totals more than £25m following a £10m donation from the Garfield Weston Foundation and other donations from entrepreneurially minded philanthropists. The target is to reach £30m by the end of 2025. The investment remit includes therapeutics, diagnostics, medical devices and data-driven and AI solutions.
Past calls and events
Photo: NAWatch the recording of KI & Cancer Research Horizons (CRH) Alliance webinar: Working together to accelerate your research
Date of webinar: 16th May 2024, 14:00 – 15:00 (CET)
In this webinar, you will learn how Cancer Research Horizons can support you translate your research findings into cancer treatments and diagnostic tools through:
Grant funding to progress drugs, devices, diagnostics, data and software
Seed and venture capital funds
Access to therapeutic discovery and development capabilities and expertise
Collaborations and alliances with industrial partners
Commercialisation of assets and tools
Entrepreneurial training programmes
Photo: NAWatch the recording of SciLifeLab, KI & Cancer Research Horizons (CRH) webinar: The importance of target validation for successful academic drug discovery
Date of webinar: 12th February 2024, 13:00– 14:30 (GMT)
In this webinar, you will learn about:
The CRH-Karolinska Institute Alliance by Richard Cowburn, KI
SciLifeLab DDD – a national infrastructure for academic Drug Discovery in Sweden, Per Arvidsson, SciLifeLab DDD
Why selecting the right target matters, Kristian Sandberg, SciLifeLab DDD
What makes a good target and how to validate it?, Stuart Farrow, CRH
Followed by a panel discussion and Q&A – What makes a good academic drug discovery program?
Moderator: Per Arvidsson, SciLifeLab DDD, Panelists: Mikael Lindström, KI, Simon Cook, Bahabram Institute, Kristian Sandberg, SciLifeLab DDD, Stuart Farrow, CRH, Richard Cowburn, KI
Photo: N/AKarolinska Institutet and Cancer Research Horizons partnership launch event
On the 15th of June 2023 the partnership launch event took place in Innomdicum auditorium Daggkåpan at Nanna Svartz väg 4. Read more about the event here.
Contact
Cancer Research Horizons
If you require more information and support from Cancer Research Horizons, please contact:
